This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page | Contact Us | Sign In | Register
Human Relevance of Rodent Liver Tumors

Organizing Committee

Chairs: Susan Felter & Jennifer Foreman
Alan Boobis - Christopher Corton - Adriana Doi - David Eastmond - Lynn Flowers
Manuela Goettel - Jay Goodman - Abigail Jacobs - James Klaunig - Anna Lowit - Jonathan Moggs
Arun Pandiri - Reza Rasoulpour

Monday | Tuesday | Wednesday

 


Monday, October 24

7:30 AM - 8:30 AM Attendee Breakfast 
(Included with Registration)
8:30 AM - 12:30 PM SESSION I: A Background on Rodent Liver Tumors and Humans and Regulatory Perspectives 
8:30 AM - 8:35 AM Welcome to the Meeting
Robert Barter, President - The Toxicology Forum 
8:35 AM - 8:45 AM Introduction to the Session and Overview
Jennifer Foreman, ExxonMobil Biomedical Sciences
8:45 AM - 9:10 AM Comparative Pathology of Proliferative Liver Lesions
David Malarkey, NIEHS, Cellular and Molecular Pathology Branch
9:10 AM - 9:35 AM Comparison of Known MOA's of Rodent (Mouse, Rat) versus Human Hepatocellular Tumors
James Popp, Stratoxon, LLC
9:35 AM - 10:00 AM Rodent Liver Tumor Response in NTP Studies
Arun Pandiri, NIEHS-NTP
10:00 AM - 10:20 AM BREAK
10:20 AM - 12:00 PM Regulatory Perspectives
Moderated by Lynn Flowers, US EPA 
10:20 AM - 10:40 AM European Regulatory Perspective: 
Jan Willem Van der Laan, Medicines Evaluation Board
10:40 AM - 11:00 AM US Regulatory Perspective: Environmental Protection Agency
Vincent Cogliano, US EPA-IRIS
11:00 AM - 11:20 AM US Regulatory Perspective: Food and Drug Administration
Abigail Jacobs, US FDA-CDER
11:20 AM - 11:40 AM European Regulatory Perspective: European Chemicals Agency
Gesine Mueller, European Chemicals Agency
11:40 AM - 12:00 PM Canadian Regulatory Perspective: Health Canada
Ivy Moffat, Health Canada 
12:00 PM - 12:30 PM Moderated Discussions
 
12:30 PM - 1:30 PM Attendee Luncheon
(Included with Registration)
1:30 PM - 5:00 PM SESSION II: CAR/PXR
Moderated by Jay Goodman, Michigan State University; Adriana Doi, BASF; and Jonathan Moggs, Novartis
1:30 PM - 1:35 PM Introduction to the Session
Jay Goodman, Michigan State University 
1:35 PM - 1:55 PM Introduction to CAR Activation and Considering This As a Key Event in Rodent Liver Tumorigenesis
Curtis Omiecinski, Penn State University
1:55 PM - 2:20 PM The Molecular Epigenetic Basis for Species-Specific Hepatic Responses to Phenobarbital
Remi Terranova, Novartis Institute for Biomedical Research
2:20 PM - 2:45 PM Constitutive Androstane Receptor (CAR) Models Including the CAR KO Sprague-Dawley Rat Model
Brian Lake, CXR Biosciences
2:45 PM - 3:10 PM Rodent Liver Tumorigens That Act by a MOA Involving Activation of CAR As a Key Event Might Present a Risk for People
Michael Schwarz, University of Tubingen
3:10 PM - 3:30 PM BREAK
3:30 PM - 3:55 PM Role of Activation of CAR and Beta-Catenin in Liver Growth and Tumorigenesis
David Moore, Baylor College of Medicine 
3:55 PM - 4:20 PM Human Relevance of Rodent Liver Tumors by Compounds Whose MOA Includes Activation of CAR As a Key Event
Brian Lake, CXR Biosciences
4:20 PM - 5:00 PM Moderated Discussions
5:30 PM - 7:00 PM Attendee Welcome Reception

 

Tuesday, October 25

7:30 AM - 8:30 AM Attendee Breakfast 
(Included with Registration)
8:30 AM - 12:00 PM SESSION III: PPARalpha-dependent Mode of Action for Liver Tumor Induction
Moderated by James Klaunig, Indiana University; Christopher Corton, US EPA; and 
Jennifer Foreman, ExxonMobil Biomedical Sciences
8:30 AM - 8:40 AM Introduction to the Session
James Klaunig, Indiana University
8:40 AM - 9:00 AM Overview of PPAR in Normal Biology and Physiology
Jennifer Foreman, ExxonMobil Biomedical Sciences
9:00 AM - 9:35 AM Proposed Mode of Action for PPARa Induced Liver Tumors
Christopher Corton, US EPA
9:35 AM - 10:10 AM Human Relevance of PPARa Induced Liver Tumors
Jeff Peters, Penn State University
10:10 AM - 10:30 AM BREAK
10:30 AM - 11:05 AM Regulatory Perspective
Lynn Flowers, US EPA
11:10 AM - 11:55 AM Moderated Discussion
James Klaunig, Indiana University and Christopher Corton, US EPA 
11:55 AM - 12:00 PM Session Wrap-up and Closing Remarks
Jennifer Foreman, ExxonMobil Biomedical Sciences 
12:00 PM - 2:00 PM Attendee Luncheon & Poster Session
(Included with Registration) 
2:00 PM - 5:00 PM SESSION IV: Cytotox/Regen MOA and New Technologies
Moderated by Susan Felter,Procter & Gamble and Alan Boobis, Imperial College London
2:00 PM - 2:05 PM Introduction to the Session and Overview
Susan Felter, Procter & Gamble 
2:05 PM - 2:30 PM Role of Cytotoxicity and Regenerative Hyperplasia in Cancer
Samuel Cohen, University of Nebraska Medical Center
2:30 PM - 3:00 PM Evidence of Cytotoxicity As a MOA and Its Human Relevance
Paolo Boffetta, Mount Sinai School of Medicine
3:00 PM - 3:30 PM Use of AOPs/MOAs to Develop Strategies for Assessing Nongenotoxic Rodent Hepatocarcinogens
Bette Meek, University of Ottawa
3:30 PM - 3:50 PM BREAK
3:50 PM - 4:20 PM New Tools to Evaluate MOA (Toxicogenomics)
David Geter, Bayer Crop Science 
4:20 PM - 5:00 PM Moderated Discussions

 

Wednesday, October 26

7:30 AM - 8:30 AM Attendee Breakfast
(Included with Registration)
8:30 AM - 1:15 PM SESSION V: Definition of Nongenotoxic; Evaluating Alternative MOAs; Case Studies; Weight of Evidence
Moderated by Susan Felter, Procter & Gamble and Todd Bourcier, US FDA-CDER
8:30 AM - 8:35 AM Introduction to the Session and Overview
Susan Felter, Procter & Gamble 
8:35 AM - 9:00 AM Human Relevance Evaluation of Rodent Liver Neoplasms
Frank Sistare, Merck
9:00 AM - 9:30 AM How Do We Define "Non-Genotoxic"
David Eastmond, University of California - Riverside 
9:30 AM - 10:00 AM Evolving the MOA Framework: A Quantitative Evidence Integration Approach for Side-by-Side Comparison of Alternative Hypothesized MOAs
Richard Becker, American Chemistry Council
10:00 AM - 10:30 AM Decisions on Cancer Hazard Classifications – How Do We Obtain Global Harmonization?  
Reza Rasoulpour, Dow AgroSciences
10:30 AM - 11:00 AM ICHS1 Expert Working Group on Carcinogenic Waiver Considerations
Todd Bourcier, US FDA
11:00 AM - 11:30 AM BREAK
11:30 AM - 12:00 PM CAR Case Study: Epsilon-Momfluorothrin 
Gesine Mueller, European Chemicals Agency
12:00 PM - 12:30 PM Case Study on Pronamide – Dual CAR/PPARalpha Mode of Action
Matthew LeBaron, Dow AgroSciences
12:30 PM - 1:15 PM Moderated Discussions
1:15 PM - 1:20 PM Closing Remarks
Susan Felter, Procter & Gamble